Objective-To investigate further the influence of the autonomic nervous system on chronic rheumatic diseases. Methods-The density and aYnity of 2 adrenergic receptors ( 2R) on CD19+ lymphocytes in patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and systemic sclerosis (SSc), as well as intracellular cAMP levels in patients with RA and SLE, were determined. Human peripheral blood mononuclear cells were separated from venous blood of patients and healthy controls by Ficoll-Hypaque density centrifugation. CD19+ lymphocytes were purified by magnetic cell sorting, and 2R were determined by a radioligand binding assay with [ 125 I]iodocyanopindolol. Intracellular cAMP levels and 2R agonist induced cell death were measured by a radioimmunoassay and flow cytometry using annexin-V binding, respectively. Systemic disease activity of the patients was evaluated using multifactorial scoring systems. Results-The density of 2R on peripheral CD19+ lymphocytes was significantly decreased in patients with RA, SLE, and SSc compared with healthy controls. In patients with RA and SSc 2R density was negatively correlated with systemic disease activity. Furthermore, although basal intracellular cAMP levels were raised in patients with RA and SLE, the increase of cAMP upon stimulation of 2R was significantly reduced in these patients compared with control subjects. Preliminary data suggest that 2R agonist induced cell death is diminished in patients with RA exhibiting decreased 2R densities. Conclusions-The results of this study show a reduction of 2R densities on B lymphocytes mirrored by an impaired intracellular cAMP generation in patients with chronic rheumatic diseases, indicating a decreased influence of the autonomic nervous system on B cells in these conditions.
I]iodocyanopindolol.
Intracellular cAMP levels and 2R agonist induced cell death were measured by a radioimmunoassay and flow cytometry using annexin-V binding, respectively. Systemic disease activity of the patients was evaluated using multifactorial scoring systems. Results-The density of 2R on peripheral CD19+ lymphocytes was significantly decreased in patients with RA, SLE, and SSc compared with healthy controls. In patients with RA and SSc 2R density was negatively correlated with systemic disease activity. Furthermore, although basal intracellular cAMP levels were raised in patients with RA and SLE, the increase of cAMP upon stimulation of 2R was significantly reduced in these patients compared with control subjects. Preliminary data suggest that 2R agonist induced cell death is diminished in patients with RA exhibiting decreased 2R densities. Conclusions-The results of this study show a reduction of 2R densities on B lymphocytes mirrored by an impaired intracellular cAMP generation in patients with chronic rheumatic diseases, indicating a decreased influence of the autonomic nervous system on B cells in these conditions. (Ann Rheum Dis 2001; 60:505-510) Although the cause of inflammatory autoimmune diseases like rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and systemic sclerosis (SSc) is unknown, it is well accepted that cellular and humoral immune responses underlie the distinct pathology of these diseases. A hallmark of chronic rheumatic diseases is the formation of autoantibodiesfor example, rheumatoid factor in RA, antibodies against double stranded DNA (dsDNA) and Smith antigen (Sm) in SLE, and against topoisomerase-II (Scl-70) in SSc. Additionally, immune complexes and hypergammaglobulinaemia are common features, indicating a B cell hyperactivity. 1 A growing body of evidence points towards a modulation of immune responses in vitro as well as in vivo and the inflammatory activity of autoimmune diseases by the autonomous nervous system. It has been shown that lymphocytes and noradrenergic varicosities form synapse-like conjunctions in lymphoid organs 2 3 and that 2 adrenergic receptors ( 2R) are expressed on various lymphocyte subpopulations. 4 5 Previous studies of our group showed that in patients with chronic rheumatic diseases the density of 2R is decreased on peripheral blood mononuclear cells (PBMC). Further investigations showed that 2R are modulated diVerentially on lymphocyte subsets because 2R densities were reduced on CD8+ lymphocytes but not on CD4+ cells. 6 7 However, little is known about 2R on B lymphocytes in these disease entities.
Therefore we investigated the characteristics of 2R on peripheral blood B lymphocytes (CD19+ mononuclear cells) in patients with RA, SLE, and SSc, together with the systemic disease activity, and determined the coupling of 2R to the intracellular signal transduction cascade.
Methods

PATIENTS AND CONTROL SUBJECTS
Patients with RA (n=24), SLE (n=13), and SSc (n=6) according to classical diagnostic criteria [8] [9] [10] and a group of healthy blood donors (n=16) were included in the study. We excluded patients in whom other factors were supposed to influence 2R (that is, infectious and atopic diseases, hyperthyroidism/ hypothyroidism, hypertonia, treatment with sympathomimetic/sympatholytic agents, cancer). 11 Patients were examined by taking a history, physical examination, and laboratory findings (erythrocyte sedimentation rate (ESR), C reactive protein (CRP), haemoglobin, packed cell volume, leucocytes, lymphocytes, platelets, autoantibodies, creatinine). Inflammatory disease activity in RA, SLE, and SSc was determined by diVerent multifactorial scoring systems. For patients with RA we used a modified total disease activity score according to Farr et al, (TAI) 12 which includes morning stiVness, the Ritchie articular index, 13 ESR, CRP, and haemoglobin. For patients with SLE the SLE activity measure (SLAM) was used.
14 For the patients with SSc a new scoring system adapted from the SLAM was developed and called the SSc score (SSS, table 1). Table 2 summarises the clinical characteristics of patients and control subjects. Treatment with non-steroidal antirheumatic drugs or steroids up to 7.5 mg prednisolone equivalent a day were allowed in all patient groups (RA 15/24 patients, range 2-7.5 mg prednisolone equivalent a day, SLE 9/13, range 2.5-7.5 mg, SSc 5/6, range 2-7.5 mg). No patient received disease modifying antirheumatic drugs. Cell death induced by isoprenaline was determined in four patients with RA and five healthy controls.
PURIFICATION OF CD19+ LYMPHOCYTES
PBMC were separated from heparinised venous blood by Ficoll-Hypaque (Seromed, Berlin, Germany) density gradient centrifugation. 15 Cells were then washed three times in phosphate buVered saline supplemented with 0.5% bovine serum albumin (PBS/BSA) and adjusted to a cell concentration of 1×10 8 /ml. CD19+ lymphocytes were purified by magnetic cell sorting. 16 To separate CD19+ cells, PBMC of patients or control subjects were incubated with a monoclonal antihuman CD19 antibody coupled to supramagnetic microparticles for 20 minutes in a refrigerator (Miltenyi Biotec, Bergisch-Gladbach, Germany). Cells were then washed in cold PBS/BSA and CD19+ cells were separated by filtration through a magnetised steel wool column (MACS cell separator, MACS column A2 and LS, Miltenyi Biotec). The eYcacy of the magnetic separation was evaluated by flow cytometry using a FACScan (Becton Dickinson, Heidelberg, Germany). The purity of the isolated CD19+ lymphocytes averaged 95% in all experiments.
DETERMINATION OF 2R
The number of 2R on purified CD19+ cells was determined as previously described. 17 In brief, aliquots of 0.6×10 6 CD19+ cells were incubated for 60 minutes at 37°C with six different concentrations of [ Filters were washed to remove unbound radioactivity, and radioactivity on wet filters was determined in a multicrystal gammacounter (LB 2103, Berthold, Wildbad, Germany). Unspecific binding of ICYP was measured in parallel by incubating the CD19+ cells in the presence of high concentrations of propranolol (1 µmol/l), a competitive antagonist of ICYP. The concentration of basal and stimulated levels of cAMP in CD19+ lymphocytes was determined in patients with RA (n=5), SLE (n=4), and controls (n=8) by a radioimmunoassay. Aliquots of 1×10 6 CD19+ cells in PBS/BSA containing 50 µM theophylline and 10 µM ascorbic acid were either incubated for 15 minutes at 37°C to determine basal cAMP levels or incubated with 10 µM (−)-isoprenaline for 15 minutes to determine stimulated cAMP levels. 19 20 After boiling and centrifugation, cAMP in the supernatant was measured by a [ 125 I]cAMP radioimmunoassay (Dianova-Imunotech, Hamburg, Germany) according to the guidelines of the manufacturer. The increase of cAMP upon 2R stimulation with isoprenaline was calculated by subtraction of basal from stimulated levels.
INDUCTION AND DETERMINATION OF CELL DEATH IN ACTIVATED CD19+ LYMPHOCYTES
Cell death induced by stimulation of 2R in activated CD19+ lymphocytes was determined in patients with RA (n=4) and control subjects (n=5). Aliquots of 2×10 5 CD19+ cells in serum free RPMI medium supplemented with penicillin/streptomycin, L-glutamine, and 2% TCH defined serum supplement (ICN, Eschwege, Germany) were activated with 1 µg/ml plate bound anti-IgM polyclonal antibody (BioSource, Camarillo, CA, USA) for 16 hours in the presence or absence of 10 µM isoprenaline. After washing in binding buVer (150 mM NaCl, 2 mM CaCl 2 , 10 mM HEPES) the number of apoptotic and necrotic cells was evaluated using annexin-V-FITC (Bender Med Systems, Vienna, Austria) and propidium iodide staining. At least 5000 events were counted on a FACScan (Becton Dickinson) using the Cell Quest software (Becton Dickinson). Spontaneous and 2R agonist induced cell death (apoptotic and necrotic cells) was determined with a histogram and two dimensional dot plots.
STATISTICAL ANALYSIS
Values in tables and figures are given as means and standard errors of the mean (SEM) if not otherwise indicated. Correlations between 2R characteristics and disease activity scores were calculated by the Pearson product moment correlation. A comparison of independent single variables between the groups was calculated by one way analysis of variance (ANOVA) followed by Tukey's procedure. When normality test failed, Kruskal-Wallis one way ANOVA on ranks was used. A comparison of isoprenaline induced cell death in patients with RA and healthy controls was calculated by a paired t test. p Values less than 0.05 were considered to be significant.
Results
2R DENSITY AND DISSOCIATION CONSTANTS
The number of 2R on CD19+ cells was significantly decreased in patients with chronic rheumatic diseases compared with control subjects (p<0.001). The mean (SEM) number of 2R was 1041 (44) binding sites (bs)/cell in patients with RA, 1278 (103) bs/cell in patients with SLE, and 1035 (83) bs/cell in patients with SSc, respectively. On CD19+ cells derived from healthy donors 2060 (106) bs/cell were detected (fig 1) . No significant diVerence was found between the 2R density in the various patient groups.
The KD values of 2R for ICYP were reduced in the patient groups (RA 5.89 (0.53) pmol/l; SLE 6.36 (0.92) pmol/l; SSc 5.9 (0.76) pmol/l) compared with the control group (9.86 (1.36) pmol/l). However, when the KruskalWallis test was used the diVerence between patient groups and control subjects did not reach significance (p=0.113).
Stratifying patients with RA and SLE according to the use of corticosteroid drugs did not disclose a diVerence in 2R characteristics between the respective groups: patients with RA receiving corticosteroid treatment 1036 (62.6) bs/cell (KD 5.9 (0.7) pmol/l; n=15) v patients with RA without corticosteroid drugs 1048 (56.2) bs/cell (KD 5.8 (0.8) pmol/l; n=9); and patients with SLE receiving corticosteroid drugs 1287 (140) bs/cell (KD 6.4 (1.2) pmol/l; n=9) v patients with SLE without corticosteroids 1273 (144) bs/cell (KD 6.3 (1.5) pmol/l; n=4).
CORRELATION OF 2R STATUS WITH DISEASE ACTIVITY IN RA, SLE, AND SSC
In patients with RA and SSc, 2R density on CD19+ lymphocytes showed a significant negative correlation with disease activity. In patients with RA a negative correlation between the 2R density and the TAI (r=−0.76, Figure 1 Density of 2 fig 2) , and in the SSc group a negative correlation with SSS (r=−0.90, p=0.01) was found. In the SLE group 2R density on CD19+ lymphocytes was negatively correlated with SLAM, but the correlation was not significant (r=−0.52, p=0.07). This was because one patient had high disease activity as well as high 2R density (fig 2) . The relative increase of cAMP above basal levels after isoprenaline stimulation was markedly decreased in RA (3.51 (1.86)%) and SLE (1.69 (0.51)%) in comparison with the control group (9.43 (1.30)%, p<0.05, fig 3) . No significant correlation was found between cAMP levels and 2R characteristics or disease activity scores, respectively.
2R AGONIST INDUCED CELL DEATH
Cell death induced by the incubation of activated CD19+ lymphocytes with 10 µM isoprenaline was investigated in patients with RA (n=4) in comparison with healthy controls (n=5). The proportion of dead cells (defined as apoptotic and necrotic cells based upon staining with annexin-V and propidium iodide, respectively) among the CD19+ cells activated with plate bound polyclonal anti-IgM antibody for 16 hours was raised in patients with RA (30.0 (3.6)%, table 3) compared with control subjects (18.9 (3.7)%). Stimulation of 2R with 10 µM isoprenaline slightly increased the number of dead cells in patients with RA (36.1 (6.7)%, relative change 18.1 (9.7)%, NS). In contrast, the number of dead cells significantly increased upon activation of 2R with isoprenaline in the control subjects (32.9 (7.5)%; p<0.05, relative change 79.7 (20.5)%; p<0.05, table 3).
Discussion
The results of our study demonstrate a profound modulation of 2R on B lymphocytes (CD19+ lymphocytes) in chronic rheumatic diseases. The density of 2R on B lymphocytes was decreased in patients with RA, SLE, and SSc compared with healthy control subjects, and a negative correlation between the 2R density on B cells and systemic disease activity scores was found in all patient groups studied except the SLE group. In addition, inducible intracellular cAMP levels in response to stimulation of 2R were reduced in Previous studies showed that 2R density was decreased on PBMC in patients with chronic rheumatic diseases. 7 17 21 Recently, it was shown that in patients with RA, 2R were diVerentially regulated in lymphocyte subpopulations because 2R on CD8+ lymphocytes were down regulated in contrast with unchanged 2R numbers on CD4+ lymphocytes. 7 When the results of these studies are taken together the picture emerges that in chronic rheumatic diseases the expression of 2R on T and B lymphocytes is a complex modulated process rather than simply down regulation.
Various mechanisms contributing to the observed diVerential modulation of 2R expression are possible. A long term increase of catecholamines decreases 2R density through the stimulation of the adrenoceptor kinase. 22 23 However, the diVerential regulation of 2R on CD4+ and CD8+ lymphocyte subsets in patients with RA argues against a simple down regulation of 2R due to an increase of systemic catecholamine concentrations, 7 as can be seen in patients with pheochromocytoma. 24 Moreover, a correlation with plasma catecholamine levels could not be shown either for systemic disease activity or for 2R density on PBMC in patients with RA. 6 The aYnity of 2R in human neutrophils and the transcription of 2R mRNA in human lung cells have been shown to be increased by corticosteroids. 25 In RA and SLE a decreased cortisol plasma concentration due to alterations in cortisol metabolism in SLE 26 27 and a disturbed adrenal secretion of cortisol in RA 28 have been proposed. Therefore, decreased cortisol concentrations are a possible mechanism for the down regulation of 2R in rheumatic diseases. However, low dose corticosteroids did not influence 2R characteristics in previous investigations, nor in the study presented here. Thus, at least in patients with chronic rheumatic diseases, low dose corticosteroids do not influence 2R characteristics of immune cells. 17 29 Other factors, such as a diVerential regulation of high and low aYnity 2R and a defect in intrinsic 2R regulation, may also contribute to the disturbed 2R expression. 30 31 Because it has been shown in this study and in previous studies that there was a striking negative correlation between 2R density and the disease activity, 6 7 it is tempting to speculate that the density of 2R on PBMC is influenced by the inflammatory process. In particular, cytokines and eicosanoids like prostaglandin E 2 are known to modulate 2R density in vitro. 32 33 Furthermore, investigations of our group showed that interleukin 2 may be a key player in modulating 2R expression diVerentially in CD4+ and CD8+ cells. 34 The generation of cAMP after stimulation of 2R with isoprenaline was impaired in B lymphocytes of patients with RA and SLE. As has been shown previously, the increase of stimulated cAMP rather than basal levels is crucial for the intracellular signal transduction. 35 It seems unlikely that changes in intracellular cAMP levels were induced by preparation of CD19 positive cells, as engagement of CD19 does not interfere with cAMP production in B cells. 36 As a functional consequence of 2R stimulation, cell death induced by isoprenaline was determined in CD19+ cells activated by B cell receptors. An increase of intracellular cAMP influences B cell function at diVerent stages and has been shown to induce apoptotic cell death in resting B cells as well as in B cells activated by the B cell receptor. [37] [38] [39] [40] [41] As our preliminary data show, the isoprenaline induced cell death of B cells is diminished in patients with RA, underlining the functional consequence of decreased 2R densities on immune cells of patients with RA.
Hence, our results indicate that the influence of the sympathetic nervous system on B lymphocytes is impaired in chronic rheumatic diseases. Together with interleukin 1 the increase of intracellular cAMP is an essential signal for the primary immune response and the diVerentiation of B cell precursors into IgM secreting cells through inactivation of protein kinase C. [42] [43] [44] In contrast, T helper cell function and the secondary immune response are inhibited by activation of 2R and an increase of intracellular cAMP. [42] [43] [44] [45] [46] An inverse eVect on T cell function could be seen after propranolol treatment and sympathectomy. 47 48 Therefore, an impaired cAMP response may have a role in the B cell dysregulation in chronic rheumatic diseases.
In conclusion, our results show that the density of 2R and the agonist induced cAMP 
